Skip to main content

Table 2 Bendamustine in clinical trials

From: Novel agents for chronic lymphocytic leukemia

Study agents

Other agents

Disease

Dose

Trials

No. of Pts

Response

Reference

Bendamustine

chlorambucil

Untreated

100 mg/m2

Phase III

305

CR:29%

[22]

ORR:68%

Bendamustine

Rituximab

Untreated

60-100 mg/m2

Retrospective

142

CR:19%

[23]

High risk

ORR:80%

Relapsed

Refractory

Bendamustine

Rituximab

Untreated

133.6-165.9

Retrospective

217

CR>19%

[24]

Prednisone

mg/m2

ORR>83%

Bendamustine

Alemtuzumab

Relapsed

50-70 mg/m2

Retrospective

50

CR:26%

[25]

Refractory

ORR:70%

Bendamustine

Fludarabine

High risk

20-50 mg/m2

Phase I/II

35

CR/CRi:26%

[26]

Rituximab

Relapsed

ORR:71%

  

Refractory

     
  1. Abbreviations: CR complete remission, CRi CR with incomplete recovery of cytopenia; ORR overall response rate.